Quarantine at a Glance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Quarantine at a Glance
A successful quarantine program requires collaboration among all departments of a pharmaceutical facility.


Pharmaceutical Technology
Volume 33, Issue 6

Quarantine database

To track the quarantine material, a database is essential. This tracking system should be designed to provide data inputs, queries, and reports associated with the discrepant material. The coordinator is responsible for entering the quarantine information within the tracking system.

The database is a key element in viewing the quarantine inventory. The database may include the following proper-

ties for each discrepant material: material description, batch number, quantity along with unit of measurement, the date the material was quarantined, and the reason why it was quarantined. The database should reference each record log number.

Management support

When developing a quarantine system within the company that wishes to engage in truly effective quarantine functions, support from the entire organization is absolutely necessary, especially from management. Without support from management, the quarantine program may not be effective and can end up with hit-or-miss results. Management should hold their direct reports accountable for ensuring the quarantine system is a reliable one.

Summary

The quarantine program should not be overlooked or given careless consideration. This program is also not a one-time event that involves one-way communication. It is a commitment between the organization's departments that should be treated as a partnership. Management should create a culture that promotes communication between the quarantine department and the entire organization to ensure control of nonconforming material.

Joanna Anglin is a quarantine coordinator at Talecris Biotheraeutics, 8368 US 70 Bus Hwy W, Clayton, NC 27520, tel. 929.359.4383, fax 919.359.4552, joanna.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here